ASH: Pfizer Sees CD70-Targeted MDS Drug As Better For Frailer Patients

The drug maker presented Phase I data for PF-08046040 at ASH, having designed it to avoid some of the toxicities associated with antibody-drug conjugates.

(Alaric DeArment/Scrip)

An increasingly popular antigen in hematology-oncology as well as solid tumor oncology is CD70, with a number of players developing therapies to target it. But Pfizer believes its PF-08046040, acquired through its purchase of Seagen, could target CD70 in a way more amenable to elderly patients.

The drug maker presented Phase I data in a poster on 7 December at the American Society of Hematology annual...

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from Therapy Areas

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.